Frazier Lifesciences Acquisition : NewAmsterdam Pharma PREVAIL Update May 2026

Published: 2026-05-07 08:05:23 ET NAMS

Published on 05/07/2026 at 08:05 am EDT

May 7, 2026

Obicetrapib's Observed MACE-4 Reduction

Methods of Estimating MACE-4 Reduction

Based on the CTT line, the expectation for a 33% reduction in LDL-C from placebo would be a 9% MACE-4 reduction, after 12 months

LDL-P reduction potentially provides 6-7% additional MACE-4 reduction

Lp(a) reduction potentially provides an additional 5% MACE-4 reduction

These elements may not be additive as they are correlated to some extent. In this scenario, there is room for additional reduction to be driving incremental gains

21%

LDL-P

LDL-C Alone

Note: Actual results may differ from hypothetical calculation.

Sources: Data on file and Cholesterol Treatment Trialists Collaboration; Folse et al. Athero 2014, Quseda et al, Atherosclerosis 35 (2023) 165-177;

Berman, A, Biery, D, Besser, S. et al. Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease. JACC. 2024 Mar, 83 (9) 873-886

3 MACE-4 includes CHD death, myocardial infarction, ischemic stroke and coronary revascularization in adults.

While not powered to detect a MACE-4 benefit, we observed positive MACE-4 data as part of our review of the exploratory endpoint. BROADWAY was not powered to measure MACE-4 benefit and the MACE-4 data

presented below may not be predictive of the MACE data we observe in PREVAIL, which has been designed to measure MACE benefit.

Kaplan Meier Curve

Landmark Analysis: Censored at 6 months

4-point MACE: CHD death, Non-fatal myocardial infarction, non-fatal stroke, coronary revascularization

4 While not powered to detect a MACE-4 benefit, we observed positive MACE-4 data as part of our review of the exploratory endpoint. BROADWAY was not powered to measure MACE-4 benefit and the MACE-4 data presented below may not be predictive of the MACE data we observe in PREVAIL, which has been designed to measure MACE benefit.

1º endpoint - week 12

N = 2532

LDL-C endpoint

N = 9541

Obicetrapib 10 mg (2:1 rand1o3m-mizoantthios n)

Placebo

13-months

Obicetrapib 10 mg (1:1 randomization)

Placebo

54-months

Key Inclusion Criteria

ASCVD or HeFH

LDL-C ≥55 mg/dL w/risk factors, or

LDL-C≥ 100 mg/dL

Maximally tolerated lipid lowering therapy

Key Inclusion Criteria

ASCVD

LDL-C ≥55 mg/dL w/risk factors, or

LDL-C≥ 100 mg/dL

Maximally tolerated lipid lowering therapy

Baseline Lipids

125

142

150

mg/dL

100

Blinded mean Median

nmol/L

Baseline Lipids

133

155

103

200

mg/dL

150

100

Blinded mean

nmol/L

Median

LDL-C Non-HDL-C ApoB HDL-C TG

Lp(a)

LDL-C Non-HDL-C ApoB HDL-C TG

Lp(a)

Baseline Lipid Modifying Therapy Baseline Lipid Modifying Therapy

Any statin: 91%

High intensity statin: 65%

Ezetimibe: 26%

PCSK9i: 4%

SGLT2i: 11%

GLP-1: 6%

Any statin: >90%

High intensity statin: 70%

Ezetimibe: 23%

PCSK9i: 2%

SGLT2i: 14%

GLP-1: 6%

5 Source: Data on file

Blinded/Blended Year 1 Event Rates

4-point MACE: CHD death, Non-fatal myocardial infarction, non-fatal stroke, coronary revascularization

(1) While not powered to detect a MACE benefit, we observed positive MACE-4 data as part of our review of the exploratory endpoint. BROADWAY was not powered to measure MACE benefit and the MACE data presented below may not be predictive of the MACE data we observe in PREVAIL, which has been designed to measure MACE benefit.

6 PREVAIL data is preliminary and subject to change as MACE events continue to be identified and adjudicated (including with respect to periods presented above). Additionally,

Year 1 and Year 2 MACE event trends may not be indicative of future trends.

Disclaimer

NewAmsterdam Pharma Company NV published this content on May 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 07, 2026 at 12:04 UTC.